BridgeBio Pharma Cash on Hand 2018-2026 | BBIO
BridgeBio Pharma cash on hand from 2018 to 2026. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- BridgeBio Pharma cash on hand for the quarter ending June 30, 2026 was $0.720B, a 4.85% decline year-over-year.
- BridgeBio Pharma cash on hand for 2025 was $0.587B, a 13.75% decline from 2024.
- BridgeBio Pharma cash on hand for 2024 was $0.681B, a 50.84% increase from 2023.
- BridgeBio Pharma cash on hand for 2023 was $0.452B, a 11.44% decline from 2022.
|
BridgeBio Pharma Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2025 | $587 |
| 2024 | $681 |
| 2023 | $452 |
| 2022 | $510 |
| 2021 | $837 |
| 2020 | $607 |
| 2019 | $546 |
| 2018 | $436 |
|
BridgeBio Pharma Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2026-06-30 | $720 |
| 2026-03-31 | $940 |
| 2025-12-31 | $587 |
| 2025-09-30 | $646 |
| 2025-06-30 | $757 |
| 2025-03-31 | $541 |
| 2024-12-31 | $681 |
| 2024-09-30 | $406 |
| 2024-06-30 | $587 |
| 2024-03-31 | $520 |
| 2023-12-31 | $452 |
| 2023-09-30 | $560 |
| 2023-06-30 | $404 |
| 2023-03-31 | $517 |
| 2022-12-31 | $510 |
| 2022-09-30 | $592 |
| 2022-06-30 | $716 |
| 2022-03-31 | $671 |
| 2021-12-31 | $837 |
| 2021-09-30 | $600 |
| 2021-06-30 | $838 |
| 2021-03-31 | $919 |
| 2020-12-31 | $607 |
| 2020-09-30 | $711 |
| 2020-06-30 | $841 |
| 2020-03-31 | $905 |
| 2019-12-31 | $546 |
| 2019-09-30 | $536 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |